Nasdaq

Monte Rosa Therapeutics Begins Phase 1 Study of MRT-8102 for Inflammatory Conditions with Initial Results Expected in H1 2026

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
Yahoo Finance

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

BOSTON, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, ...
Nasdaq

Monte Rosa Therapeutics To Unveil Interim MRT-8102 Phase 1 Study Results

(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE), a clinical-stage biotechnology company, is scheduled to highlight interim clinical results from the ongoing Phase 1 study of MRT-8102, being developed ...
Seeking Alpha

Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC

The last time I spoke about Monte Rosa Therapeutics (GLUE) it was with respect to a Seeking Alpha article I wrote titled "Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash." With ...
Seeking Alpha

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, ...